Influence of frusemide on cis-dichlorodiammineplatinum (II) pharmaco-kinetics

Cis-dichlorodiammineplatinum (CDDP) pharmacokinetics were evaluated in eighteen patients with cancer who received 80 mg/m2 CDDP as a 20 min infusion. One hour before, 10 of them had 20 mg/m2 frusemide. Fifteen blood samples and fifteen urine samples were collected over the 5 hours following the infu...

Full description

Saved in:
Bibliographic Details
Published in:European journal of drug metabolism and pharmacokinetics 1987-07, Vol.12 (3), p.203-206
Main Authors: DUMAS, M, D'ATHIS, P, DE GISLAIN, C, LAUTISSIER, J. L, AUTISSIER, N, ESCOUSSE, A, GUERRIN, J
Format: Article
Language:English
Subjects:
Antineoplastic agents
Biological and medical sciences
Cisplatin - pharmacokinetics
Furosemide - pharmacology
General aspects
Humans
Kidney Diseases - metabolism
Medical sciences
Pharmacology. Drug treatments
Platinum - blood
Platinum - urine
Spectrophotometry, Atomic
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cis-dichlorodiammineplatinum (CDDP) pharmacokinetics were evaluated in eighteen patients with cancer who received 80 mg/m2 CDDP as a 20 min infusion. One hour before, 10 of them had 20 mg/m2 frusemide. Fifteen blood samples and fifteen urine samples were collected over the 5 hours following the infusion of CDDP. Platinum was assayed by flameless atomic absorption. The data did not detect any difference between patients with or without frusemide for the following platinum parameters: plasma concentration, urinary concentration, cumulative urinary excretion, renal clearance. These results suggest that frusemide has no influence upon cisplatin (CDDP) pharmacokinetics and if it protects the kidneys, it is not via kinetic modifications.
ISSN:0378-7966
2107-0180
DOI:10.1007/BF03189898